{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:45:12Z","timestamp":1765889112695,"version":"build-2065373602"},"reference-count":51,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Psoriasis is a chronic and inflammatory condition that has a huge impact on the patient\u2019s quality of life. Biological treatment improved psoriasis therapy, with impressive results seen in the evolution of the disease and the patient\u2019s quality of life. However, the risk of mycobacterium tuberculosis (MTB) infection reactivation is well-known to biological therapy, which raises problems especially in an endemic country. Materials and Methods: In this study, we followed moderate to severe psoriasis patients who had latent tuberculosis infection (LTBI) following treatment with a biological therapy approved in Romania. Results: The patients were evaluated at baseline and then followed-up with Mantoux tests and chest X-rays every year, resulting in 54 patients being diagnosed with LTBI. At the initial evaluation, 30 patients with LTBI were identified, and 24 more were identified during biological therapy. These patients were given prophylactic treatment. Out of the 97 participants in this retrospective study, 25 required association of methotrexate (MTX) alongside biological therapy. We compared the prevalence of positive Mantoux tests in patients with combined therapy with that of patients only on biological treatment, and the results were higher in the combined therapy group. Conclusion: All the patients in the study were vaccinated against tuberculosis (TB) after birth, and none were diagnosed with active tuberculosis (aTB) before or after the start of therapy according to the pulmonologist.<\/jats:p>","DOI":"10.3390\/medicina59061015","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T01:36:28Z","timestamp":1684978588000},"page":"1015","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: Real-World Data from a Care Center in Romania"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8389-1563","authenticated-orcid":false,"given":"Doriana-Sorina","family":"Lupea-Chilom","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Medicine and Pharmacy \u201cVictor Babe\u015f\u201d, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caius Silviu","family":"Solovan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Medicine and Pharmacy \u201cVictor Babe\u015f\u201d, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona Sorina","family":"Farcas","sequence":"additional","affiliation":[{"name":"Department of Microscopic Morphology\u2014Genetics, Center of Genomic Medicine, University of Medicine and Pharmacy \u201cVictor Babes\u201d, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4301-2279","authenticated-orcid":false,"given":"Armand","family":"Gogulescu","sequence":"additional","affiliation":[{"name":"Department of Medical Rehabilitation, University of Medicine and Pharmacy \u201cVictor Babe\u015f\u201d, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-4234","authenticated-orcid":false,"given":"Nicoleta Ioana","family":"Andreescu","sequence":"additional","affiliation":[{"name":"Department of Microscopic Morphology\u2014Genetics, Center of Genomic Medicine, University of Medicine and Pharmacy \u201cVictor Babes\u201d, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_3","unstructured":"Colombo, D., and Perego, R. (2013). Psoriasis\u2014Types, Causes and Medication, IntechOpen."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Okubo, Y., Tang, A.C., Inoue, S., Torisu-Itakura, H., and Ohtsuki, M. (2021). Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245732"},{"key":"ref_5","first-page":"39","article-title":"Biologic Treatments of Psoriasis: An Update for the Clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Motolese, A., Ceccarelli, M., Macca, L., Pomi, F.L., Ingrasciotta, Y., Nunnari, G., and Guarneri, C. (2022). Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020228"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijid.2022.05.029","article-title":"Prevalence trends of latent tuberculosis infection at the global, regional, and country levels from 1990\u20132019","volume":"122","author":"Ding","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2147\/JEP.S265632","article-title":"Experimental Pharmacological Management of Psoriasis","volume":"13","author":"Campione","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.imbio.2010.09.003","article-title":"The immune responses of central and effector memory BCG-specific CD4+ T cells in BCG-vaccinated PPD+ donors were modulated by Treg cells","volume":"216","author":"Li","year":"2011","journal-title":"Immunobiology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"828939","DOI":"10.1155\/2013\/828939","article-title":"Risk Factors for Tuberculosis","volume":"2013","author":"Narasimhan","year":"2013","journal-title":"Pulm. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"adv00821","DOI":"10.2340\/actadv.v102.1982","article-title":"Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy","volume":"102","author":"Mastorino","year":"2022","journal-title":"Acta Derm.-Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4103\/idoj.IDOJ_698_20","article-title":"Latent tuberculosis in psoriasis patients planned for systemic therapy\u2014A prospective observational study","volume":"12","author":"Dabbas","year":"2021","journal-title":"Indian Dermatol. Online J."},{"key":"ref_14","unstructured":"European Centre for Disease Prevention and Control, and WHO Regional Office for Europe (2021). Tuberculosis Surveillance and Monitoring in Europe 2021\u20132019 Data."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/TCRM.S347748","article-title":"Tuberculosis Surveillance in Romania Among Vulnerable Risk Groups Between 2015 and 2017","volume":"18","author":"Munteanu","year":"2022","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.5009\/gnl19209","article-title":"Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries","volume":"14","author":"Banerjee","year":"2020","journal-title":"Gut Liver"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1046306","DOI":"10.3389\/fphar.2023.1046306","article-title":"Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review","volume":"14","author":"Jahnich","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/bjd.13539","article-title":"Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry","volume":"172","author":"Gisondi","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_19","first-page":"608","article-title":"Safety of Low Dose Methotrexate (MTX) and Tuberculosis (TB)","volume":"72","author":"Davidson","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e15006","DOI":"10.1111\/ijcp.15006","article-title":"Association between different systemic therapies and the risk of tuberculosis in psoriasis patients: A population-based study","volume":"75","author":"Ting","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"924718","DOI":"10.3389\/fimmu.2022.924718","article-title":"Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living with HIV","volume":"13","author":"Freeman","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00011-005-1355-8","article-title":"Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines","volume":"54","author":"Herman","year":"2005","journal-title":"Inflamm. Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"De Medeiros, V.L.S., Santos, F.C.F., Montenegro, L.M.L., Silva, M.D.C., De Souza, V.M.O., Neto, R.G.D.L., Moura, L.C.R.V., and Magalh\u00e3es, V. (2020). TST conversions and systemic interferon-gamma increase after methotrexate introduction in psoriasis patients. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0242098"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00431-012-1783-8","article-title":"Tuberculin skin test in bacille Calmette\u2013Gu\u00e9rin-vaccinated children: How should we interpret the results?","volume":"171","author":"Mellado","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Barbisan, F., Motta, J.D.R., Trott, A., Azzolin, V., Dornelles, E.B., Marcon, M., Algarve, T.D., Duarte, M.M.M.F., Mostardeiro, C.P., and Unfer, T.C. (2014). Methotrexate-Related Response on Human Peripheral Blood Mononuclear Cells May Be Modulated by the Ala16Val-SOD2 Gene Polymorphism. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107299"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.semarthrit.2018.03.018","article-title":"High rates of tuberculin skin test positivity due to methotrexate therapy: False positive results?","volume":"48","author":"Alperi","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/ard.2007.076406","article-title":"Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: Experience from an urban arthritis clinic","volume":"67","author":"Mor","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/rheumatology\/37.10.1136","article-title":"Cavitary lung tuberculosis in a rheumatoid arthritis patient treated with low-dose methotrexate and steroid pulse therapy","volume":"37","author":"Pappone","year":"1998","journal-title":"Rheumatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/rheumatology\/40.3.341","article-title":"Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis","volume":"40","author":"Binymin","year":"2001","journal-title":"Rheumatology"},{"key":"ref_30","unstructured":"(2023, March 05). Treatment Regimens for Latent TB Infection, Center for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/tb\/topic\/treatment\/ltbi.htm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/ajt.15841","article-title":"Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"20","author":"Sterling","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000501989","article-title":"Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis","volume":"11","author":"Ribero","year":"2019","journal-title":"Case Rep. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/jdv.16866","article-title":"Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis\u2014Time for a paradigm change","volume":"35","author":"Nogueira","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/sj.jidsymp.5650027","article-title":"Tumor Necrosis Factor and Tuberculosis","volume":"12","author":"Lin","year":"2007","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04146.x","article-title":"How tumour necrosis factor blockers interfere with tuberculosis immunity","volume":"161","author":"Harris","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/07853890.2014.941919","article-title":"Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: A systematic review of randomized controlled trials","volume":"46","author":"Lorenzetti","year":"2014","journal-title":"Ann. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ni1449","article-title":"IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge","volume":"8","author":"Bell","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cyto.2007.11.022","article-title":"IL-23 and IL-17 in tuberculosis","volume":"41","author":"Khader","year":"2008","journal-title":"Cytokine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_40","first-page":"2392","article-title":"The influence of TB chemoprophylaxis in patients with moderate to severe psoriasis treated with biological agents. A regional experience","volume":"2","author":"Neamtiu","year":"2015","journal-title":"Rom. J. Clin. Exp. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhou, S., and Yao, Z. (2022). Roles of Infection in Psoriasis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23136955"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2050313X231152054","DOI":"10.1177\/2050313X231152054","article-title":"Case of resolution of plaque psoriasis following treatment with rifampicin for latent tuberculosis: A case report","volume":"11","author":"Muntyanu","year":"2023","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3892\/etm.2021.9999","article-title":"Infection-provoked psoriasis: Induced or aggravated (Review)","volume":"21","author":"Teng","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2340\/00015555-1106","article-title":"Patients with Psoriasis are More Likely to be Treated for Latent Tuberculosis Infection Prior to Biologics than Patients with Inflammatory Bowel Disease","volume":"91","author":"Bassukas","year":"2011","journal-title":"Acta Dermato-Venereologica"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000222431","article-title":"Tuberculin Skin Test Overestimates Tuberculosis Hypersensitivity in Adult Patients with Psoriasis","volume":"219","author":"Tsiouri","year":"2009","journal-title":"Dermatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1590\/S0365-05962011000400014","article-title":"Investiga\u00e7\u00e3o de infec\u00e7\u00e3o tuberculosa latente em pacientes com psor\u00edase candidatos ao uso de drogas imunobiol\u00f3gicas","volume":"86","author":"Lima","year":"2011","journal-title":"An. Bras. Dermatol."},{"key":"ref_47","first-page":"747204","article-title":"Psoriatic Disease and Tuberculosis Nowadays","volume":"2012","author":"Balato","year":"2012","journal-title":"J. Immunol. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"13030\/qt8s09h73j","DOI":"10.5070\/D3208023525","article-title":"Risk of tuberculosis with the use of anti-TNF medications in psoriasis: Incidence, screening and management","volume":"20","author":"Kasiraman","year":"2014","journal-title":"Dermatol. Online J."},{"key":"ref_49","first-page":"257","article-title":"Recent developments in treatment of latent tuberculosis infection","volume":"133","author":"Menzies","year":"2011","journal-title":"Indian J. Med. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jdv.16254","article-title":"Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: A systematic review","volume":"34","author":"Fowler","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13030\/qt58j4n38m","DOI":"10.5070\/D3249041425","article-title":"Tuberculosis and interleukin blocking monoclonal antibodies: Is there risk?","volume":"24","author":"Kelsey","year":"2018","journal-title":"Dermatol. Online J."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1015\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:41:09Z","timestamp":1760125269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["medicina59061015"],"URL":"https:\/\/doi.org\/10.3390\/medicina59061015","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,5,24]]}}}